First-in-Human Exploratory Single Ascending Dose of GLPG0974

NCT01496937 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLPG0974
DRUG: GLPG0974

Sponsor

Lakefront Biotherapeutics NV